MA-ALIRA-HEALTH
16.11.2021 15:03:04 CET | Business Wire | Press release
Alira Health (http://www.alirahealth.com/ ), a global health care consultancy, announced that it has acquired Patchai, a digital health technology company headquartered in Italy. Patchai offers intelligent digital health solutions that engage and empower patients in clinical research and care pathways, enabling better self-management of their health conditions, improving adherence to study protocols and care plans, while facilitating care delivery for clinicians with robust, real-time data. Patchai’s Co-PRO® suite of technologies personalizes patient experience, ensuring high patient satisfaction and retention in decentralized clinical trials. This is Alira Health’s second digital health acquisition, furthering the company’s rapid expansion into patient-centric, technology-enabled solutions for healthcare providers, payers, and suppliers.
“Alira Health is investing heavily in the use of technology to boost patient engagement, improve clinical trials, and collect and apply valuable real-world evidence. We are committed to humanizing health care through innovative, patient-centric technology solutions. Our acquisition of Patchai is a strategic step in realizing our vision of being the market leader in technology used for the collection of patient data in real world studies,” said Gabriele Brambilla, Co-Founder and CEO of Alira Health.
“Patchai’s mission is to advance life sciences with intelligent and human-centered solutions to channel and magnify the positive impact that bio-pharmaceutical companies, healthcare professionals and patients have on the future of health systems," said Alessandro Monterosso, Co-Founder and CEO of Patchai. “We are extremely pleased to join Alira Health and be part of their mission to transform healthcare globally by engaging patients at every step of their journey.”
Patchai has developed an intelligent platform embedding an empathetic virtual companion to deliver personalized human centric interactions to patients and collect Real World Data in real time. Preliminary data on patients using Patchai technology shows a patients’ protocol adherence up to 95%, significantly higher than other digital solutions on the market today and up to nine times higher than paper-based solutions. Patchai was accelerated by Plug and Play Tech Center in Silicon Valley and was finalist at the Catapult Awards, one of the flagship programs of EIT Health. The company, now part of Alira Health, will continue to advance its technologies to offer scalable and modular solutions for Decentralized Clinical Research and Virtual standard care.
About Patchai
Founded in 2018, Patchai’s vision is to make clinical research and routine care more engaging, smart and accessible to improve people’s quality of life. Patchai developed an intelligent platform for patient engagement and real-time data capture in decentralized clinical research and standard care. It enables clinical research and standard clinical practice to become more humane, connected and streamlined. In 2021, Patchai has been included in the Global Top 100 Digital Health Companies by The Medical Futurist Institute.
Learn more at www.patchai.io .
About Alira Health:
Alira Health is an international patient-centric and technology-enabled advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Alira Health has offices in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Bologna and Verona, Italy; Basel, Switzerland; and Cambridge, UK.
Learn more at www.alirahealth.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma’s Morcamilast (ME3183) was Granted Orphan Medicinal Product Designation by the European Commission for Palmoplantar Pustulosis3.3.2026 02:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodiesterase-4 (PDE4) inhibitor, has been granted orphan medicinal product designation by the European Commission (EC) for the treatment of palmoplantar pustulosis (PPP). Palmoplantar pustulosis is a chronic inflammatory disease characterized by the development of multiple sterile pustules on the palms and soles. Patients often experience pain and pruritus of the skin, and the condition can be accompanied by nail involvement and joint pain. Because lesions on the palms are visible to others and lesions on the soles can cause pain while walking, daily functioning can be significantly restricted, leading in a substantial reduction in quality of life. PPP has a pathophysiology distinct from psoriasis and pustular psoriasis, and treatment can be challenging, unde
IFF Completed the Divestiture of Soy Crush, Concentrates and Lecithin Businesses2.3.2026 22:15:00 CET | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its soy crush, concentrates and lecithin businesses to Bunge. This transaction does not include IFF’s soy isolates business. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260302231096/en/
Verimatrix ReAccess Earns Gold 2026 Merit Award for Telecom & Wireless2.3.2026 17:50:00 CET | Press release
Regulatory News: Verimatrix (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that its Verimatrix ReAccess solution was honored with a gold 2026 Merit Award for Telecom & Wireless. The industry accolade recognizes the company’s next-generation content security solution that modernizes legacy Conditional Access Systems (CAS) across DVB, IPTV and OTT networks without requiring costly hardware replacements or field service interventions. Judged by industry executives, media professionals and technology consultants, the Merit Awards evaluate submissions from across the telecommunications landscape. Verimatrix ReAccess enables secure, over-the-air (OTA) software updates to deployed set-top boxes (STBs), delivering operator cost savings, reduced operational complexity, and ongoing protection against piracy. It also empowers operators to continuously strengthen content security, eliminating the need for costly hardware replacements. U
Textron Aviation Launches Donation Campaign to Support 2026 Special Olympics Airlift; Continues Nationwide Call for Volunteer Doves2.3.2026 17:00:00 CET | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced the launch of a donation campaign benefitting Special Olympics in support of the 2026 Special Olympics Airlift, a nationwide effort that brings athletes and coaches to the Special Olympics USA Games through the generosity of volunteer pilots, aircraft owners and operators known as Doves. Financial contributions go directly to the Special Olympics, a 501(c)(3) charitable organization. New for the 2026 event, the donation campaign serves a vital role in ensuring each delegation has what it needs for a smooth and welcoming travel experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302196418/en/ Textron Aviation launches donation campaign to support 2026 Special Olympics Airlift; continues nationwide call for volunteer Doves (Photo credit: Textron Aviation). “This campaign reflects the spirit of unity and generosity that defines the Special Olym
Forrester Announces The Agenda For Its 2026 CX Events To Help Address The Challenges AI Can’t Handle Alone2.3.2026 15:30:00 CET | Press release
The global event series will bring together customer experience, marketing, and digital business leaders at CX Forum East, CX Forum West, and CX Summit EMEA Forrester (Nasdaq: FORR) today announced the agenda for its global customer experience (CX) event series: CX Summit EMEA, being held in Amsterdam, June 8–10, 2026; CX Forum East, being held in New York City, June 16–17, 2026; and CX Forum West, being held in San Francisco, June 29–30, 2026. Today, CX, marketing, and digital business leaders are under mounting pressure to leverage AI to architect smarter end-to-end customer journeys, automate service, operationalize AI agents, and deliver true personalization at scale — all while consumer trust is at an all-time low. While AI is promising to raise the bar for speed and efficiency, beneath every customer experience is a foundation that AI alone can’t build. To forge trust, organizations need to embed human creativity, context, customer identity, and quality data into every customer i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom